

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Wikberg *et al.*Appl. No. *To be assigned*(Continuation of U.S. Appl. No. 08/387,805.
§ 371 Date: February 21, 1995)Filed: *Herewith*For: **Human Melanocyte Stimulating
Hormone Receptor Polypeptide
and DNA (as amended)**Art Unit: *To be assigned*Examiner: *To be assigned*

Atty. Docket: 1808.0010002/MAC/MBT

J1046 U.S. PTO
10/052545

**Claim For Priority Under 35 U.S.C. § 119(a)-(d) In Utility
Application**

Commissioner for Patents
Washington, D.C. 20231

Sir:

Priority under 35 U.S.C. § 119(a)-(d) is hereby claimed to the following priority documents, filed in a foreign country within twelve (12) months prior to the filing of the above-referenced United States utility patent application:

Country	Priority Document Appl. No.	Filing Date
Denmark	DK 1046/92	August 21, 1992
Denmark	DK 1118/92	September 10, 1992
Denmark	DK 0528/93	May 5, 1993

A certified copy of each listed priority document was submitted in the parent application no. 08/387,805. Acknowledgment of this claim was made in the parent application.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Michele A. Cimbala
Attorney for Applicants
Registration No. 33,851

Date: 1/23/02

1100 New York Avenue, N.W., Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

P- USERS MTUNG 1808 002 Claimtopriority